Effects of irbesartan on inflammatory cytokine concentrations in patients with chronic glomerulonephritis

Internal Medicine

Volumn 52, Issue 3, 2013, Pages 303-308

  Tsuruoka, Shuichi ^a   Kai, Hirayasu ^a   Usui, Joichi ^a   Morito, Naoki ^a   Saito, Chie ^a   Yoh, Keigyo ^a   Yamagata, Kunihiro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Adiponectin; Angiotensin receptor blocker; Chronic glomerulonephritis; Inflammatory cytokine; Proteinuria

Indexed keywords

ADIPONECTIN; AMLODIPINE; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CYTOKINE; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 6; IRBESARTAN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; BODY MASS; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE URINE LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MALE; OBESITY; POTASSIUM BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; UREA NITROGEN BLOOD LEVEL; URINALYSIS;

ADIPONECTIN; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIPHENYL COMPOUNDS; BODY MASS INDEX; C-REACTIVE PROTEIN; CHRONIC DISEASE; CYTOKINES; FEMALE; GLOMERULONEPHRITIS; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LEPTIN; MALE; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; PROTEINURIA; TETRAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873487059     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.9066     Document Type: Article

References (20)

1. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA. Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 14: 3217-3232, 2003.
2. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 32: 3-107, 2009.
3. Bramlage P, Durand-Zaleski I, Desai N, Pirk O, Hacker C. The value of irbesartan in the management of hypertension. Expert Opin Pharmacother 10: 1817-1831, 2009.
4. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109: 2054-2057, 2004.
5. Doehner W, Todorovic J, Kennecke C, et al. Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: A randomized double-blinded placebo-controlled study. Int J Cardiol 161: 137-142, 2012.
6. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2: 550-562, 2007.
7. Chen HM, Li SJ, Chen HP, Wang QW, Li LS, Liu ZH. Obesityrelated glomerulopathy in China: a case series of 90 patients. Am J Kidney Dis 52: 58-65, 2008.
8. Ahima RS. Linking adiponectin to proteinuria. J Clin Invest 118: 1619-1622, 2008.
9. Eda S, Kaufmann J, Roos W, Pohl S. Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range. J Clin Lab Anal 12: 137-144, 1998.
10. Nishimura A, Sawai T. Determination of adiponectin in serum using a latex particle-enhanced turbidimetric immunoassay with an automated analyzer. Clin Chim Acta 371: 163-168, 2006.
11. Misra A, Garg A. Leptin, its receptor and obesity. J Investig Med 44: 540-548, 1996.
12. Derosa G, Cicero AF, D'Angelo A, et al. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factoralpha. Hypertens Res 29: 849-856, 2006.
13. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001.
14. Perico N, Remuzzi A, Sangalli F, et al. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 9: 2308-2317, 1998.
15. Parhofer KG, Munzel F, Krekler M. Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study. Cardiovasc Diabetol 6: 36, 2007.
16. Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 6: 12, 2007.
17. Negro R, Formoso G, Hassan H. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest 29: 957-961, 2006.
18. Iwai M, Kanno H, Senba I, Nakaoka H, Moritani T, Horiuchi M. Irbesartan increased PPARgamma activity in vivo in white adipose tissue of atherosclerotic mice and improved adipose tissue dysfunction. Biochem Biophys Res Commun 406: 123-126, 2011.
19. Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 118: 1645-1656, 2008.
20. Clasen R, Schupp M, Foryst-Ludwig A, et al. PPARgammaactivating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46: 137-143, 2005.